Showing results (661-670 of 1,188) with videos related to
Sort By:
Pageof 119
Journal of Hematology & Oncology|May 9, 2015
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseasesChi Young Ok, Keyur P Patel, Guillermo Garcia-Manero, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemiaWilliam Wierda, Susan O'Brien, Sijin Wen, et al.American Journal of Hematology|July 4, 2014
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemiaGautam Borthakur, Jorge E Cortes, Elihu E Estey, et al.Annals of Hematology|March 28, 2025
A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndromeGuillermo Garcia-Manero, Manila Gaddh, Uwe Platzbecker, et al.Oncotarget|February 13, 2016
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agentsKoichi Takahashi, Keyur Patel, Carlos Bueso-Ramos, et al.Kidney International Supplements|January 25, 2019
Action plan for optimizing the design of clinical trials in chronic kidney diseaseVlado Perkovic, Jonathan C Craig, Worawon Chailimpamontree, et al.Leukemia Research|February 16, 2006
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndromeKaren W L Yee, Jorge Cortes, Alessandra Ferrajoli, et al.American Journal of Hematology|August 6, 2013
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitorsLorenzo Falchi, Hagop M Kantarjian, Xuemei Wang, et al.Leukemia & Lymphoma|February 11, 2020
LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agentsKelly S Chien, Caleb A Class, Guillermo Montalban-Bravo, et al.American Journal of Hematology|August 19, 2015
Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?Amer M Zeidan, Mikkael A Sekeres, Xiao-Feng Wang, et al.Pageof 119